Second Line clinical trials

Immunotherapy biomarkers for advanced lung cancer

This study looks at blood and tissue biomarkers to predict how well immunotherapy (with or without chemotherapy) works for advanced non-small cell lung cancer. It also helps decide the best second treatment if the first one stops working.

Six-week medicine switch for schizophrenia after first treatment failure

This trial tests whether a more intensive medication approach for schizophrenia (or related conditions) helps people who didn’t improve on their first tried medicine. Participants will usually switch medicines and be compared against “treatment as usual.”

Six-week medicine boost for depression after first treatment failure

This study tests a more intensive antidepressant medicine approach for people whose first tried treatment didn’t work well enough. It compares the intensified treatment with usual care, aiming to improve depression symptoms and daily functioning.

NALIRIFOX chemo for advanced neuroendocrine cancer after first treatment

This trial tests a combination chemotherapy called NALIRIFOX as a second treatment for people with advanced high-grade neuroendocrine cancers. The goal is to see if it can help when the first treatment didn't work.

Second-line therapy for advanced colorectal cancer

This trial tests a combination of chemotherapy with either bevacizumab or cetuximab as a second-line treatment for advanced colorectal cancer. It aims to find which option works better for patients whose first treatment failed.

New Immunotherapy Combination for Advanced Head and Neck Cancer

This trial tests a new combination of two immunotherapy drugs (called iparomlimab and tuvonralimab), with or without chemotherapy, for head and neck squamous cell carcinoma that has returned or spread after previous treatment. The goal is to see if this combination can help people with this cancer live longer with fewer side effects.

A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer

Nemtabrutinib plus venetoclax versus standard add-on therapy

This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.

Oral Paclitaxel Plus Fruquintinib for Advanced Stomach Cancer

This trial tests a combination of two oral drugs (paclitaxel and fruquintinib) for advanced stomach cancer that has already been treated with one round of chemotherapy. The goal is to see if this combination helps control the cancer better than other standard second-line treatments.

Comparing Two Chemo Combos for Advanced Bile Duct Cancer

This trial compares two chemotherapy combinations (mFOLFOX and mFOLFIRI) against just one of them (mFOLFOX) for people with advanced bile duct or gallbladder cancer that has progressed after standard first-line treatment. The goal is to see which works better as a second treatment option.

Second-line treatment for warm autoimmune anemia

This Phase 3 study tests a second-line treatment for adults with warm autoimmune hemolytic anemia whose disease is not controlled with steroids, who cannot tolerate steroids, or who decline standard treatment. It aims to improve anemia and reduce ongoing red blood cell destruction caused by the immune system.

New drug combo for advanced pancreatic cancer

This trial tests a new drug called ONT01 combined with two standard chemo drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread and is no longer responding to first treatment. The goal is to see if this new combination can help control the cancer.

Testing RC48 and Tislelizumab for recurrent cervical cancer with HER2

This trial tests a combination of two drugs, RC48 and Tislelizumab, for people with recurrent cervical cancer whose tumors have a protein called HER2. The goal is to see if this treatment can help when previous therapy has stopped working.

Freezing treatment plus immunotherapy and a pill for liver cancer

This trial tests whether freezing (cryoablation) combined with tislelizumab and lenvatinib can help shrink advanced liver cancer and improve outcomes after earlier treatments stopped working or caused side effects. It may be an option if your cancer can’t be removed with surgery and you’ve already tried one prior systemic (whole-body) treatment.

Liver artery chemotherapy for non-surgical bile duct cancer

This trial tests delivering two chemotherapy medicines directly into the liver’s artery in people with bile duct cancer inside the liver that cannot be removed with curative surgery. It aims to control the cancer after first-line treatment and see how well this targeted approach works.

Vaccine, immunotherapy, and radiation for advanced lung cancer

This trial tests a combination of a personalized peptide vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation for people with advanced non-small cell lung cancer whose disease has gotten worse after at least two standard treatments. It aims to see if this triple therapy can help control the cancer.

Glufosfamide vs 5-FU for metastatic pancreatic cancer after gemcitabine

This study compares two chemotherapy drugs—glufosfamide and 5-FU—in people with pancreatic cancer that has spread and got worse after gemcitabine. It aims to see which option works better as a “second-line” treatment.

New drug combo for advanced stomach cancer after first treatment fails

This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.

Vaccine, immunotherapy, and radiation for advanced lung cancer

This trial tests a combination of a personalized cancer vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation therapy for people with advanced non-small cell lung cancer that has gotten worse after at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow cancer growth.

Upadacitinib vs. Infliximab for Severe Ulcerative Colitis

This study compares two medications—upadacitinib and infliximab—as second-line treatments for acute severe ulcerative colitis (a serious flare of inflammatory bowel disease). The trial will help doctors understand which treatment works better when standard first-line therapy hasn't controlled the inflammation.

Chidamide, Sintilimab, and Bevacizumab for Advanced Neuroendocrine Cancer

This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.

Immunotherapy after first treatment for extensive stage small cell lung cancer

This trial tests immunotherapy drugs for extensive stage small cell lung cancer that has progressed after initial (first-line) chemotherapy. You may be eligible if you have finished standard treatment and your cancer has worsened.

Asciminib for second-line chronic phase CML

This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.

Fruquintinib, adebrelimab, and radiation for advanced colorectal cancer

This trial tests a combination of two drugs (fruquintinib and adebrelimab) plus low or high dose radiation for people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow the disease.